The increasing prevalence of multidrug-resistant (MDR) bacterial infections presents a major challenge to modern healthcare, particularly in hospitals where delays in identifying pathogens and their resistance mechanisms can compromise treatment decisions. Conventional microbiological culture remains fundamental to bacterial identification and antimicrobial susceptibility testing; however, its relatively long turnaround time has encouraged the development of faster molecular and genomic approaches. Polymerase chain reaction (PCR), multiplex molecular assays, CRISPR-based diagnostics, next-generation sequencing (NGS), and metagenomic next-generation sequencing (mNGS) are expanding the capacity of clinical laboratories to detect bacterial pathogens and investigate antimicrobial resistance. These technologies differ in analytical sensitivity, specificity, turnaround time, cost, and clinical applicability. Although molecular diagnostics can provide actionable information earlier than conventional methods in selected settings, the detection of a resistance gene does not always establish the complete resistance phenotype, and the identification of microbial DNA does not necessarily prove active infection. This article reviews the principles, clinical applications, advantages, and limitations of these technologies and discusses their potential role in developing more precise, timely, and evidence-based approaches to managing MDR bacterial infections.
Keywords: Multidrug-resistant bacteria; molecular diagnostics; PCR; CRISPR diagnostics; next-generation sequencing; metagenomic sequencing; antimicrobial resistance.
1. Introduction
Antimicrobial resistance (AMR) is one of the most significant challenges facing contemporary medicine. The emergence and dissemination of bacteria resistant to multiple antimicrobial agents threaten the effectiveness of established treatments, increase the complexity of clinical management, and place additional pressure on healthcare systems. The World Health Organization’s 2024 Bacterial Priority Pathogens List highlights the importance of resistant organisms, including carbapenem-resistant Acinetobacter baumannii, resistant Enterobacterales, Pseudomonas aeruginosa, and drug-resistant Mycobacterium tuberculosis [1].
The management of these infections depends not only on the availability of effective antimicrobial agents but also on the ability to identify the causative pathogen and determine its likely susceptibility profile in a clinically useful timeframe. Conventional culture-based methods remain indispensable because they demonstrate viable organisms and enable phenotypic antimicrobial susceptibility testing. Nevertheless, culture may require prolonged incubation, and prior antimicrobial exposure, low pathogen burden, or difficult-to-cultivate organisms may reduce diagnostic yield.
Molecular diagnostics have therefore become increasingly important in clinical microbiology. By detecting pathogen-specific nucleic acids, resistance-associated genetic markers, or broader microbial genetic material, these methods can complement conventional laboratory procedures and support earlier clinical decision-making. Their value is greatest when results are interpreted alongside the patient’s clinical presentation, specimen quality, epidemiological context, and conventional microbiological findings.
2. PCR-Based Diagnostics: A Foundation of Rapid Detection
The polymerase chain reaction (PCR) is one of the most established molecular methods in infectious disease diagnosis. It amplifies selected DNA sequences, enabling the detection of specific microorganisms or genetic markers even when the target material is present in relatively small quantities.
Real-time PCR, also known as quantitative PCR (qPCR), monitors amplification as it occurs and can provide results without the need for post-amplification gel electrophoresis. Multiplex PCR allows several targets to be examined in a single reaction, making it particularly useful when the clinical presentation is compatible with infections caused by multiple potential pathogens.
In the investigation of MDR bacterial infections, molecular assays may detect bacterial species and selected resistance-associated genes, such as mecA/mecC in methicillin-resistant Staphylococcus aureus and vanA/vanB associated with vancomycin resistance in enterococci. Depending on the assay, molecular testing may also identify selected carbapenemase genes in resistant Gram-negative bacteria.
The principal advantage of PCR-based testing is speed. In appropriately selected clinical settings, results may become available substantially earlier than conventional culture and susceptibility testing. This can support earlier optimization of antimicrobial therapy, improved infection-control decisions, and more targeted diagnostic investigations.
However, PCR has important limitations. Most targeted assays detect only the organisms or genetic markers included in their design. An unanticipated pathogen or an unrepresented resistance mechanism may therefore be missed. Furthermore, the detection of a resistance-associated gene does not invariably establish the organism’s complete phenotypic susceptibility profile. Conversely, resistance may arise through mechanisms not covered by the assay. For these reasons, molecular results should be interpreted within the scope of the specific test and, where indicated, supplemented by culture and phenotypic susceptibility testing.
3. CRISPR-Based Diagnostics: A Developing Platform
Clustered regularly interspaced short palindromic repeats (CRISPR) and their associated proteins have attracted considerable interest as tools for nucleic acid detection. Certain CRISPR-associated enzymes, including Cas12 and Cas13, can be programmed to recognize specific DNA or RNA sequences. Under suitable assay conditions, target recognition triggers detectable signals that can be used to identify the presence of selected genetic sequences.
CRISPR-based diagnostic platforms are being investigated for rapid pathogen identification and the detection of antimicrobial resistance-associated markers. Their potential advantages include high sequence specificity, flexible assay design, and opportunities to develop compact diagnostic systems. When combined with suitable nucleic acid amplification methods, some approaches may be adapted to settings with limited laboratory infrastructure.
Nevertheless, CRISPR-based diagnostics are not a single standardized technology, and their performance depends on the target, assay design, specimen type, sample preparation, and validation process. Many applications remain under development or require further clinical evaluation before routine implementation. Questions concerning assay standardization, diagnostic accuracy across diverse patient populations, regulatory approval, cost, and integration into existing laboratory workflows must be addressed before broad adoption.
Accordingly, CRISPR diagnostics should be regarded as a promising and evolving complement to established methods rather than a universal replacement for culture, PCR, or antimicrobial susceptibility testing.
4. Next-Generation Sequencing and Resistance Characterization
Next-generation sequencing (NGS) enables the analysis of large quantities of genetic information in parallel. In clinical microbiology, sequencing may be applied to DNA obtained from a cultured isolate or, in selected circumstances, directly from a clinical specimen.
Whole-genome sequencing of bacterial isolates can provide detailed information about species identity, genetic relationships between strains, resistance-associated genes, and selected mutations. These data are valuable for investigating healthcare-associated outbreaks, tracking the transmission of resistant organisms, and supporting epidemiological surveillance.
Sequencing can also reveal genetic features that are not included in a conventional targeted molecular panel. This broader scope is particularly useful when investigating unusual resistance patterns or suspected transmission between patients and healthcare environments.
However, genomic prediction is not equivalent to direct measurement of antimicrobial susceptibility. The clinical significance of a detected gene or mutation depends on its biological function, expression, genetic context, and the organism in which it occurs. Not every resistance mechanism is fully characterized, and genotype–phenotype discrepancies may occur. Consequently, sequencing findings should be interpreted using validated databases and established interpretive frameworks, with phenotypic susceptibility testing retained where clinically indicated.
5. Metagenomic Next-Generation Sequencing: Beyond Targeted Detection
Metagenomic next-generation sequencing (mNGS) represents a broader approach to infectious disease investigation. Rather than testing exclusively for a predefined pathogen, mNGS analyzes genetic material within a specimen to identify microbial sequences without requiring the laboratory to select a single organism in advance.
This approach may be particularly useful in complex diagnostic situations, including infections in which conventional investigations are inconclusive, unusual organisms are suspected, or prior antimicrobial treatment has reduced the likelihood of successful culture. Depending on the specimen and analytical method, mNGS may identify bacterial, viral, fungal, or parasitic genetic material within the same investigation.
The potential breadth of mNGS is accompanied by substantial interpretive challenges. Clinical specimens contain human nucleic acids and may contain environmental or reagent-derived microbial sequences. Low-abundance organisms may be difficult to distinguish from background contamination, while the detection of microbial genetic material does not necessarily indicate viable organisms or causation of the patient’s illness.
Additional limitations include cost, the need for specialized laboratory and bioinformatics expertise, variable turnaround time, and the difficulty of translating complex sequencing results into immediate treatment decisions. Resistance genes may be detected without sufficient information to establish which organism carries them or whether they are functionally expressed. Therefore, mNGS is best considered a complementary diagnostic approach for carefully selected cases rather than a universal first-line test.
6. Integrating Molecular Findings with Conventional Microbiology
The greatest clinical benefit is likely to arise from combining molecular methods with established microbiological procedures rather than treating them as competing alternatives.
A practical diagnostic strategy begins with clinical assessment and appropriate specimen collection. Depending on the suspected infection, targeted PCR or multiplex testing may provide early information about the likely pathogen. Culture remains important for recovering viable bacteria and enabling phenotypic antimicrobial susceptibility testing. Where the clinical question requires broader investigation, isolate sequencing or mNGS may offer additional information that targeted assays cannot provide.
The interpretation of results should consider the following principles:
• Pathogen detection is not synonymous with disease: Molecular detection must be assessed in the context of clinical findings, specimen quality, and the possibility of colonization or contamination.
• Resistance genes are not a complete susceptibility report: Genetic markers can support resistance prediction, but they do not necessarily capture every resistance mechanism or replace phenotypic testing.
• Negative results require contextual interpretation: A negative molecular result does not exclude infection if the organism or target is not covered by the assay, the specimen is inadequate, or the target concentration is below the detection limit.
• Clinical utility depends on timely interpretation: A technically accurate result has limited value if it is not communicated promptly or does not inform a relevant clinical decision.
Effective implementation also requires coordination among clinical microbiologists, infectious disease specialists, laboratory scientists, pharmacists, and infection-prevention teams. Diagnostic stewardship is essential to ensure that the right test is used for the right patient at the right time.
7. Artificial Intelligence and the Future of Molecular Diagnostics
The growing volume of molecular and sequencing data has increased interest in artificial intelligence (AI) and machine learning for diagnostic interpretation. These approaches may help integrate genomic features, laboratory results, epidemiological information, and clinical variables to support pathogen classification or resistance prediction.
Their usefulness, however, depends on the quality and representativeness of the data used to develop and validate the models. Differences in bacterial populations, resistance patterns, laboratory platforms, and patient characteristics can limit generalizability. Algorithmic predictions should therefore be clinically validated, transparently evaluated, and used to support—not replace—professional judgement.
Future developments are likely to focus on faster sample preparation, improved point-of-care platforms, more reliable resistance prediction, standardized interpretation, and the integration of molecular results into laboratory information systems and antimicrobial stewardship programs. In resource-limited settings, affordability, infrastructure, workforce training, and equitable access will be as important as analytical performance.
8. Conclusion
Advances in PCR, CRISPR-based diagnostics, NGS, and metagenomic sequencing are expanding the diagnostic options available for multidrug-resistant bacterial infections. Each technology offers distinct advantages, but each also has limitations that influence its appropriate clinical use. PCR provides targeted and often rapid detection; CRISPR-based platforms offer an evolving approach to sequence-specific diagnostics; isolate sequencing supports detailed genomic characterization and surveillance; and mNGS can broaden the search for pathogens when conventional or targeted approaches are insufficient.
No single method can answer every diagnostic question. The most effective strategy is an integrated approach that combines clinical assessment, appropriate specimen collection, molecular detection, conventional culture, phenotypic susceptibility testing, and responsible interpretation of genomic evidence. By applying these tools selectively and strengthening laboratory–clinical collaboration, healthcare systems can improve the timeliness and precision of diagnosis and support more informed decisions in the ongoing effort to combat antimicrobial resistance.